An update from Moderna ( (MRNA) ) is now available.
Moderna, Inc. has showcased significant progress and strategic shifts in its R&D day event, with a promising pipeline of respiratory and non-respiratory vaccines. The company anticipates regulatory submissions for a next-generation COVID vaccine and a flu/COVID combo vaccine in 2024, along with positive Phase 3 results for its RSV vaccine. Moderna is also advancing in oncology, rare diseases, and other vaccines, aiming for ten product approvals by 2027 and cutting R&D expenses by $1.1 billion. The updates signal Moderna’s commitment to addressing critical health challenges while optimizing its financial strategy for sustained growth.
See more insights into MRNA stock on TipRanks’ Stock Analysis page.
